Improved overall survival of metastatic renal cell carcinoma patients in the era of modern tyrosine kinase inhibitors and immune checkpoint inhibitors: results from a real-life, population-based Austrian study comprising three decades of follow-up
- PMID: 36425872
- PMCID: PMC9679616
- DOI: 10.1177/17588359221134065
Improved overall survival of metastatic renal cell carcinoma patients in the era of modern tyrosine kinase inhibitors and immune checkpoint inhibitors: results from a real-life, population-based Austrian study comprising three decades of follow-up
Abstract
Background: The treatment landscape of metastatic renal cell carcinoma (mRCC) has substantially advanced over the last three decades, whereby data from controlled clinical trials indicate significant improvements regarding patients' overall survival (OS) in highly selected patient cohorts. The aim of this study is to evaluate the impact of potentially game changing drugs on patients' outcomes by comparing three different historical mRCC treatment eras.
Methods: In all, 914 mRCC patients who were diagnosed between July 1985 and September 2020 were included into this observational study and assigned to three different treatment eras ['cytokine', 'first-generation tyrosine kinase inhibitors (TKIs)', and 'modern TKIs/immunotherapy'] based on the EMA approval dates of sunitinib (July 2006) and nivolumab (June 2015) in mRCC treatment. OS was considered the primary study endpoint. Kaplan-Meier analyses, log-rank tests, and uni- and multivariable Cox regression models were performed.
Results: OS was significantly longer in patients of the modern TKIs/immunotherapy era (median OS not reached) as compared to the cytokine (2.4 years) and first-generation TKIs era (1.7 years, all p < 0.001). Moreover, patients of the modern TKIs/immunotherapy era demonstrated a significantly better prognosis [hazard ratio (HR): 0.41, 95% confidence interval (CI): 0.32-0.55, p < 0.001] compared to those of the cytokine era, while no statistically significant difference was observed between the cytokine and the first-generation TKIs era cohort (HR: 1.12, 95% CI: 0.89-1.41, p = 0.341). Subgroup analyses stratified by the International Metastatic RCC Database Consortium (IMDC) risk groups showed a significantly longer OS in the modern TKIs/immunotherapy era as compared to first-generation TKIs and cytokines across all IMDC risk groups.
Conclusion: Significant advances in the systemic medical treatment of mRCC during the recent decade and the introduction of immunotherapy exerted a major impact on patient outcomes in terms of OS in a real-life population.
Keywords: immunotherapy; interferon; outcomes; renal cell carcinoma; tyrosine kinase inhibitors.
© The Author(s), 2022.
Conflict of interest statement
The authors declare that there is no conflict of interest.
Figures




Similar articles
-
Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials.Eur Urol Focus. 2022 Mar;8(2):514-521. doi: 10.1016/j.euf.2021.03.001. Epub 2021 Mar 11. Eur Urol Focus. 2022. PMID: 33714725 Review.
-
Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model.Oncologist. 2017 Mar;22(3):286-292. doi: 10.1634/theoncologist.2016-0078. Epub 2017 Feb 20. Oncologist. 2017. PMID: 28220024 Free PMC article.
-
Does the Timing of Cytoreductive Nephrectomy Impact Outcomes? Analysis of REMARCC Registry Data for Patients Receiving Tyrosine Kinase Inhibitor Versus Immune Checkpoint Inhibitor Therapy.Eur Urol Open Sci. 2024 Mar 25;63:71-80. doi: 10.1016/j.euros.2024.02.001. eCollection 2024 May. Eur Urol Open Sci. 2024. PMID: 38572300 Free PMC article.
-
Impact of Complete Surgical Resection of Metastatic Lesions in Patients with Advanced Renal Cell Carcinoma in the Era of Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors.Cancers (Basel). 2024 Feb 19;16(4):841. doi: 10.3390/cancers16040841. Cancers (Basel). 2024. PMID: 38398232 Free PMC article.
-
Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma.Eur Urol. 2019 Jan;75(1):111-128. doi: 10.1016/j.eururo.2018.09.016. Epub 2018 Oct 25. Eur Urol. 2019. PMID: 30467042
Cited by
-
Radiomics to predict immunotherapy efficacy in advanced renal cell carcinoma: A retrospective study.Hum Vaccin Immunother. 2023 Dec 31;19(1):2172926. doi: 10.1080/21645515.2023.2172926. Epub 2023 Feb 1. Hum Vaccin Immunother. 2023. PMID: 36723981 Free PMC article.
-
Stereotactic Body Radiotherapy for Extracranial Oligometastatic Renal Cell Carcinoma: State of the Art and Future Perspectives.Technol Cancer Res Treat. 2025 Jan-Dec;24:15330338251357344. doi: 10.1177/15330338251357344. Epub 2025 Jul 17. Technol Cancer Res Treat. 2025. PMID: 40671563 Free PMC article. Review.
References
-
- Siegel RL, Miller KD, Fuchs HE, et al.. Cancer statistics, 2021. CA Cancer J Clin 2021; 71: 7–33. - PubMed
-
- Ljungberg B, Albiges L, Abu-Ghanem Y, et al.. European association of urology guidelines on renal cell carcinoma: the 2019 update. Eur Urol 2019; 75: 799–810. - PubMed
-
- Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005; 353: 2477–2490. - PubMed
LinkOut - more resources
Full Text Sources
Research Materials